Viatris Inc

Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that provides a broad portfolio spanning generics, value-added medicines, established brands, and innovative medicines addressing areas of significant unmet need. The company operates through four geographic segments — Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets — and categorizes its products into Brands and Generics. Key products include well-known established brands such as Lipitor, Norvasc, Lyrica, Viagra, EpiPen Auto-Injectors, Creon, Celebrex, Zoloft, Effexor, and Xalabrands, along with specialty products like Yupelri, Dymista, Amitiza, and Xanax. Viatris is actively developing its pipeline with assets including Gwyn Lo (a low-dose contraceptive patch recently approved by the FDA), MR-107A-02 (fast-acting meloxicam, a non-opioid analgesic under FDA review), VR-205/Nefecon for IgA nephropathy, and generic ferric carboxymaltose injection. The company pursues a balanced capital allocation strategy combining shareholder returns through dividends and share repurchases with debt reduction and disciplined business development, including distribution agreements for biosimilar products and co-promotion partnerships. Viatris maintains a global manufacturing and distribution network and serves patients across more than 165 countries. Updated Aug 6, 2026